| NCT ID | Title | Status | Phases | Start Date | Completion Date | Primary Completion Date |
|---|---|---|---|---|---|---|
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-09-08 | 2025-12 | 2025-12 |